Uncategorized Archives - Page 42 of 145

MondayDec 05, 2022 9:45 am

MetAlert Inc. (MLRT) Announces Canadian Distributor Launch of Award-Winning 4G GPS SmartSole Medical Monitoring Device for Alzheimer’s, Dementia, and Autism

ARPA-H is investing a billion dollars to encourage cutting-edge research for Alzheimer's, supporting bold ideas to pursue and drive new biomedical breakthroughs The Department of Health and Human Services is investing in research and technology to help keep Alzheimer's patients in their homes longer, train caregivers to support them, and educate Americans about Alzheimer's early warning signs – all of which MetAlert provides products and solutions for The Alzheimer’s Disease diagnostic and therapeutic market is expected to reach an estimated $9.6 billion by 2027 MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, has announced…

FridayDec 02, 2022 11:59 am

Research Discovers That Survivors of Pediatric Cancer Are Prone to Premature Aging

Every year, an estimated 400 children and adolescents aged 19 and under are diagnosed with cancer. Leukemia, brain tumors, solid tumors such as neuroblastomas and lymphomas tend to be the most common types of pediatric cancer, with more than 80% of patients in high-income nations such as the United States receiving treatment. Even though pediatric cancer treatment can be quite cost intensive, childhood cancer can generally be cured via surgery, radiotherapy, chemotherapy and generic medicines. However, a recent study has revealed that patients who survive pediatric cancer aren’t completely out of the woods even after they are in remission. The…

ThursdayDec 01, 2022 9:00 am

Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023

Odyssey is set to hold its Annual Meeting of Stockholders on January 12, 2023 The meeting promises an excellent podium to update shareholders on the company’s progress throughout the 2022 calendar year as well as its plans for the future Odyssey has so far achieved vital milestones such as progress in its ONP-002 novel compound on the treatment of concussions, patent protection filing for its Nasal Device, and the expansion of its executive team It looks to take advantage of the meeting to draw stockholders' views and opinions on specific topics while also offering them a platform to contribute to…

TuesdayNov 29, 2022 12:00 pm

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases

In collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, BiondVax is developing a pipeline of NanoAb therapies The company’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his work describing protein transport within the cell The global market for autoimmune disorder therapies is expected to reach $90.7 billion by 2024; The global market for infectious disease therapeutics is expected to reach $167 billion by 2030 BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biotechnology company…

TuesdayNov 29, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Development of Neuropharmaceuticals for TBIs and CNS Maladies, Portends Competitiveness in Area of Unmet Medical Needs

A growing chorus of concerns about brain concussions resulting from athletic events is helping to propel new interest in developing pharmaceuticals to treat this “unmet medical need” Concussion treatments have largely focused on simple rest, but medical product developer Odyssey Health Inc. is developing a potential treatment to reduce brain inflammation so needed therapy can get to the site of a brain injury Odyssey is also developing solutions for other central nervous system troubles, such as the highly fatal childhood disease Niemann-Pick type C, and nerve gas exposure sickness The neuropharmaceutical market is forecast to have a great deal of…

MondayNov 28, 2022 9:06 am

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastoma CNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in France CNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy, with 29 of 68 anticipated sites currently enrolling patients The company expects to provide an interim analysis of the trials in mid-2023 and primary completion in 2024, with ultimate resolution in 2025 The FDA has…

WednesdayNov 23, 2022 11:15 am

MetAlert Inc. (MLRT) Is ‘One to Watch’

MetAlert’s management team is highly experienced (several previous exits) in the tech, apparel, and wearable medical device industries, with significant management ownership (70%+) in MLRT The company operates in a large and growing global market in terms of potential revenue ($20-$50+ per month) and number of users (34+ million), with a potential impact on hundreds of millions The recent pandemic created an emphasis on health monitoring, especially for at-risk consumers/patients The recent pandemic negatively impacted the supply chain and shipping, creating a backlog of orders, but recent months’ activity suggests that the supply chain and shipping issues will be resolved…

WednesdayNov 23, 2022 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Announces New Chief Medical Officer

New Chief Medical Officer will play a major role in defining best paths to adoption, clinical strategies, and partnerships Dr. Fitzgerald serves as director of the Center for Cardiovascular Technology and of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School Dr. Fitzgerald brings impressive expertise in the clinical, research and industry sectors In a display of its commitment to offering innovative, high-quality products and services, cardiac tech company HeartBeam (NASDAQ: BEAT) has named a world-renowned interventional cardiologist with an impressive breadth of experience as its Chief Medical Officer (https://ibn.fm/pN1kf). Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help…

TuesdayNov 22, 2022 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event

BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration. The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025 The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque…

TuesdayNov 22, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBM Berubicin is a novel anthracycline and the first to appear to cross the blood-brain barrier The global GBM treatment market is expected to reach a value of $4.2 billion by 2028, driven by the increased approval granted by the FDA for novel GBM treatment therapies CNS Pharmaceuticals (NASDAQ: CNSP),…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

MetAlert Inc. (MLRT) Announces Canadian Distributor Launch of Award-Winning 4G GPS SmartSole Medical Monitoring Device for Alzheimer’s, Dementia, and Autism

Research Discovers That Survivors of Pediatric Cancer Are Prone to Premature Aging

Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases

Odyssey Health, Inc. (ODYY) Development of Neuropharmaceuticals for TBIs and CNS Maladies, Portends Competitiveness in Area of Unmet Medical Needs

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

MetAlert Inc. (MLRT) Is ‘One to Watch’

HeartBeam Inc. (NASDAQ: BEAT) Announces New Chief Medical Officer

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search